PF-05230907 / Pfizer - LARVOL DELTA

Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage. (PubMed, Stroke) - P1b | "Single doses of PF-05230907 appeared to be tolerated across a range of doses in the intracerebral hemorrhage population, with thrombotic events observed only at the highest dose level tested. Recruitment within the recommended therapeutic window of opportunity remains a challenge."

Clinical • Journal • P1 data • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Thrombosis • Venous Thromboembolism